Roche COVID-19 Response | Questions About Our Medicines? Visit medinfo.roche.com
Retrospective analysis: clinical outcomes in patients treated with EGFR TKIs in Taiwan
Patients treated with erlotinib had similar overall survival and PFS to those patients treated with gefitinib or afatinib, despite having the highest proportion of brain metastases at baseline.1
Study overview1
- This retrospective analysis examined clinical outcomes and secondary T790M mutations in Taiwanese patients with EGFR Mut+ NSCLC, treated with first-line erlotinib, gefitinib or afatinib.
Key Results1
Baseline characteristics
Baseline characteristics were unbalanced across the treatment groups
Overall survival1
Overall survival did not differ among the treatment groups.
Progression-free survival1
PFS did not differ among the treatment groups.
Data of preparation February 2020- M-XX-00000785 - © 2020
This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) the United Kingdom (UK), and Australia (AU) who are interested in information on TARCEVA®. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.